Medetomidine Hydrochloride CAS 86347-15-1 | Pharmaceutical Chemical
Medetomidine hydrochloride (CAS No. 86347-15-1) is a highly potent and selective α2-adrenoceptor agonist. It exhibits a high affinity (Ki) of 1.08 nM for α2-receptors and demonstrates approximately 1,620-fold greater selectivity for α2-receptors compared to α1-receptors.
Pharmacologically, the compound produces significant sedative, analgesic, and anxiolytic effects, as well as a reduction in body temperature. Its applications fall into two main categories:
Veterinary medicine: Widely used as a sedative and an agent for inducing general anesthesia in animals such as dogs and cats.
Human medicine and scientific research: In the United States, it was previously FDA-approved for the sedation of intubated patients in intensive care units (ICUs). In scientific research, it serves as a common pharmacological tool in neuroscience studies. Its effects can be rapidly reversed by specific antagonists (such as atipamezole).
As a chemical substance, it has the molecular formula C₁₃H₁₆N₂·HCl and a molecular weight of 236.74; it typically appears as a white to off-white crystalline powder. Notably, the substance possesses high acute toxicity (e.g., it can be fatal if ingested or inhaled) and is extremely toxic to aquatic life; strict safety protocols must be observed during handling.
Medetomidine hydrochloride, a highly potent and selective α2-adrenoceptor agonist, is primarily utilized in the fields of veterinary medicine and biomedical research.
Veterinary Medicine: Sedation, Analgesia, and Anesthesia Adjunct for Dogs and Cats
In companion animal medicine, medetomidine hydrochloride is a widely used sedative and analgesic. Approved for use in dogs and cats, its primary applications include:
Clinical Examinations and Procedures: It provides sedation and analgesia for dogs and cats, facilitating clinical examinations, diagnostic imaging (such as X-rays or ultrasound), dermatological checks, ear treatments, wound management, and procedures such as venipuncture.
Pre-anesthetic Medication: Used as a pre-anesthetic agent, it significantly reduces the dosage of other anesthetic drugs required for subsequent induction and maintenance (by 30%–60% in dogs), thereby enhancing anesthetic safety.
Regarding administration, it can be given to dogs via intramuscular or intravenous injection, while intramuscular injection is the standard route for cats. Onset of action typically occurs within 5–15 minutes of administration, with sedative and analgesic effects peaking at approximately 30 minutes.
Biomedical Research: Functional MRI and Neuroscience Studies
Due to its property of inducing "arousable sedation"—where the animal remains sedated yet maintains neural activity levels close to the waking state—medetomidine hydrochloride has become an ideal anesthetic adjunct for animal experiments.
It has been repeatedly demonstrated to effectively reduce stress responses and head-motion artifacts in animals—particularly during functional magnetic resonance imaging (fMRI)—thereby yielding higher-quality image data. Unlike anesthetics that deeply suppress the central nervous system, medetomidine better preserves functional connectivity networks in the brain, a factor crucial for studying brain functional activity.